FGEN FibroGen, Inc

24.10
-1.5  -5.86%
Previous Close 25.60
Open 25.50
Price To book 9.05
Market Cap 1.52B
Shares 63,160,000
Volume 757,581
Short Ratio 7.30
Av. Daily Volume 542,564

SEC filingsSee all SEC filings

  1. CT ORDER - Confidential treatment order 162060656
  2. 8-K - Current report 162000559
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981401
  4. 8-K - Current report 161981318
  5. S-8 - Securities to be offered to employees in employee benefit plans 161904477

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from China trial due early 2017. Possibly due January or February.
Roxadustat FG-4592
Anemia in chronic kidney disease
Phase 2 trial enrollment commenced January 2016. Continues to enroll as of November 2016.
FG-3019
Duchenne muscular dystrophy
Phase 2 ongoing in Hong Kong. Future development uncertain
FG-3019
Liver fibrosis
Phase 2 ongoing. Two-thirds of patients enrolled as of February 2016. Enrolment to be completed 3Q 2016. Data due mid 2017.
FG-3019
Idiopathic pulmonary fibrosis
Phase 2 ongoing. Data likely due at ASCO GI January 19-21, 2017. Abstract released on January 17.
FG-3019
Pancreatic cancer

Latest News

  1. FibroGen (FGEN) Shares March Higher, Can It Continue?
  2. 5:08 pm FibroGen reports updated results from ongoing clinical study of pamrevlumab (FG-3019) with 'promising' safety and efficacy observed
  3. Pamrevlumab Pancreatic Cancer Clinical Data Presented at ASCO 2017 Gastrointestinal Cancers Symposium
  4. Here Are Two Market Moving Biotech Catalysts To Watch This Week
  5. 6 Major FDA Decisions and Biopharma Catalysts Coming in January and February
  6. Better Buy: Organovo Holdings, Inc. vs. Akebia Therapeutics, Inc.
  7. Will 2017 Be a Make or Break Year for FibroGen?
  8. FibroGen, Inc. – Value Analysis (NASDAQ:FGEN) : December 23, 2016
  9. FibroGen, Inc. breached its 50 day moving average in a Bearish Manner : FGEN-US : December 22, 2016
  10. Why Akebia Therapeutics Inc Stock Zoomed Higher Today
  11. Akebia Funds Late-Stage Studies of Anemia Pill With Partnership for U.S. Commercial Rights
  12. ETFs with exposure to FibroGen, Inc. : December 16, 2016
  13. Is FibroGen Inc (FGEN) a Good Stock to Buy?
  14. GSK chases Astra with start of big anaemia drug trials
  15. ETFs with exposure to FibroGen, Inc. : November 18, 2016
  16. FIBROGEN INC Financials
  17. FibroGen, Inc. :FGEN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 16, 2016
  18. FIBROGEN INC Files SEC form 8-K, Change in Directors or Principal Officers
  19. FibroGen, Inc. breached its 50 day moving average in a Bullish Manner : FGEN-US : November 11, 2016
  20. Edited Transcript of FGEN earnings conference call or presentation 8-Nov-16 9:30pm GMT

SEC Filings

  1. CT ORDER - Confidential treatment order 162060656
  2. 8-K - Current report 162000559
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981401
  4. 8-K - Current report 161981318
  5. S-8 - Securities to be offered to employees in employee benefit plans 161904477
  6. CT ORDER - Confidential treatment order 161842253
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161814280
  8. 8-K - Current report 161814149
  9. 8-K - Current report 161783054
  10. 8-K - Current report 161709379